Posted on

cbd oil for kidney cancer

Loss of appetite is common when you have cancer. Fortunately, cannabis is famous for giving people “the munchies.” If you’re experiencing a lack of appetite, these strains may help:

Tinctures and sprays absorb through your mouth. They take a while to kick in and can be expensive.


You’ll have plenty of opportunities to look through the menu of available medical cannabis products throughout that time. Plus, your budtender can answer any questions about the various strains and products available. If you’re looking for a strain that helps stimulate your appetite, just ask. Or if you’re looking for the most popular strain for curbing nausea related to chemotherapy for kidney cancer, you’re budtender can point you in the right direction.

There are three main types of kidney cancer. Renal cell cancer is the most common in adults. Transitional cell cancer is also common in adults. Wilms tumors are more common in children.

Daniel Sennert made the earliest known reference to kidney tumors back in 1613, as reported by Wellington School of Medicine and Health Sciences. The first description of renal carcinoma was in 1810. In 1957, thalidomide went on the market as an immunomodulatory drug. It’s still used today in cancer treatment. The establishment of Nephrology as the study of the kidney and its functions occurred in 1960, and the founding of the Kidney Cancer Association occurred in 1990.

The outcomes of interest were any objective evidence of anticarcinogenic or antiproliferative activity of cannabinoids in male urological malignancies either through in vitro or in vivo studies. The cancers of interest are renal, ureteric, bladder, prostate, and urethral neoplasms.

We conducted a systematic review of studies exploring the effect of cannabinoids on tumour activity, including all study types except expert opinions. A formal search was run on Medline database from 1946 to September 2016, along with a hand-search on PubMed for relevant studies.

Selection of studies

The search yielded a total of 93 studies from Medline and PubMed, of which 23 studies were included in the final analysis. To date, there are various in vitro studies elucidating the potential mechanism of action of cannabinoids for urological cancers, along with population-based studies specifically for testicular malignancies. To date, no clinical trials have been conducted for urological cancer patients.

Overall, the above studies have shown the presence of CB1 receptors in clear-cell renal cell carcinoma and chromophobe renal cell carcinoma, and in vitro experiments also point to the possible role of down-regulation of CB1 receptors in promoting clear-cell renal neoplasm cell proliferation. The receptors could not only play an important role in investigating treatment options, but could also be used for diagnostic purposes.

In summary, although many studies have explored the in vitro mechanisms and population-based evidence for cannabinoids, there have been no clinical trials to date for urological patients. Currently, there is no conclusive evidence to support patient claims for starting on cannabinoid monotherapy for anticancer benefit when all other avenues for therapy have failed. Thus, further research is required not only to evaluate the crosstalk between cancer signaling pathways and the ECS, but also large randomized clinical studies with urological patients need to be conducted before cannabinoids can be introduced as potential therapeutic options for urological neoplasms.